Exploratory positional differences in observed CDRH2 lineage-state transitions following HIV-1 germline-targeting vaccination
Abstract
Background: Germline-targeting HIV-1 vaccination recruits VRC01-class B-cell precursors, but the positional patterns of observed longitudinal B-cell receptor lineage-state changes remain incompletely described. We compared CDRH2 profiles between homologous and heterologous boosting regimens using published IAVI G002 data. Methods: Participant-specific Week-8 lineages were prospectively matched to Week-24 observations. Germline-to-nongermline changes in sampled lineage-modal residues were evaluated at seven IGHV1-2*02 CDRH2 positions using participant-balanced, mean-centered profiles and exact participant-label permutation inference. Sampling-depth and sorting-probe sensitivity analyses assessed observability. A separate participant-held-out benchmark evaluated antibody-language-model representations for predicting observed Week-24 lineage detection. Results: The CDRH2 analysis included 332 lineages, 15 participants, 2,179 eligible lineage-position observations, and 241 observed state changes. The regional profile statistic was 0.027066 (exact p = 0.001709; six-region adjusted q = 0.010256), with descriptive differences at V-relative positions 51, 54, and 55. Most eligible longitudinal observations had one assessable cell per visit. In seven Group-1 participants, Week-24 dual-probe sampling recovered 181 baseline lineages with eOD-GT8 and 143 with Cg28v2, including 60 detected by both probes. In a separate cohort of 2,739 lineages from 17 participants, IgBERT and AbLang-2 representations did not improve participant-balanced average precision over a four-feature biological baseline. Conclusions: Observed CDRH2 lineage-modal-state profiles differed between regimens in this exploratory secondary analysis. Sparse sampling, potentially probe-related ascertainment, and absent linked functional validation preclude inference about mutation timing, functional improvement, or causal booster effects.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Asymmetric Boost Responses to an HIV-1 Vaccine: Boost-site Controls Secondary B-cell Fates
John S. Barber, Keisuke Tonouchi, … Garnett H. Kelsoe·bioRxiv·Aug 19, 2026
- Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naive human B cells
- Mixed Origins: HIV gp120-specific memory develops from pre-existing memory and naive B cells following vaccination in humans
M. Basu, M. S. Piepenbrink, … J. J. Kobie·bioRxiv·Sep 1, 2021
- Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans
Tom G. Caniels, Madhu S. Prabhakaran, … Rogier W. Sanders·bioRxiv·Oct 26, 2026
- Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity
David Easterhoff, Justin Pollara, … Guido Ferrari·bioRxiv·May 9, 2019
- Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial
Xiaohe Lin, Christopher A. Cottrell, … Ian A. Wilson·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 11, 2025